Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension

References

• PeacockAJMurphyNFMcMurrayJJCaballeroLStewartSAn epidemiological study of pulmonary arterial hypertensionEur Respir J200730110410917360728
   PubMed Web of Science ®Google Scholar
• BenzaRLMillerDPBarstRJBadeschDBFrostAEMcGoonMDAn evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL RegistryChest2012142244845622281797
   PubMed Web of Science ®Google Scholar
• SimonneauGGatzoulisMAAdatiaIUpdated clinical classification of pulmonary hypertensionJ Am Coll Cardiol20136225 SupplD34D4124355639
   PubMed Web of Science ®Google Scholar
• ChesterAHYacoubMHThe role of endothelin-1 in pulmonary arterial hypertensionGlob Cardiol Sci Pract201420142627825405182
   PubMedGoogle Scholar
• ChristmanBWMcPhersonCDNewmanJHAn imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertensionN Engl J Med1992327270751603138
   PubMed Web of Science ®Google Scholar
• IgariHTatsumiKSugitoKRole of EDRF in pulmonary circulation during sustained hypoxiaJ Cardiovasc Pharmacol19983122993059475273
   PubMed Web of Science ®Google Scholar
• TuderRMCoolCDGeraciMWProstacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertensionAm J Respir Crit Care Med199915961925193210351941
   PubMed Web of Science ®Google Scholar
• GalieNGhofraniHATorbickiASildenafil citrate therapy for pulmonary arterial hypertensionN Engl J Med2005353202148215716291984
   PubMed Web of Science ®Google Scholar
• GubrijIBMartinSRPangleAKKurtenRJohnsonLGAttenuation of monocrotaline-induced pulmonary hypertension by luminal adeno-associated virus serotype 9 gene transfer of prostacyclin synthaseHum Gene Ther201425649850524512101
   PubMed Web of Science ®Google Scholar
• GalieNManesABranziAThe endothelin system in pulmonary arterial hypertensionCardiovasc Res200461222723714736539
   PubMed Web of Science ®Google Scholar
• GiaidAYanagisawaMLanglebenDExpression of endothelin-1 in the lungs of patients with pulmonary hypertensionN Engl J Med199332824173217398497283
   PubMed Web of Science ®Google Scholar
• StewartDJLevyRDCernacekPLanglebenDIncreased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?Ann Intern Med199111464644691994793
   PubMed Web of Science ®Google Scholar
• ChannickRNSimonneauGSitbonOEffects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled studyLancet200135892881119112311597664
   PubMed Web of Science ®Google Scholar
• GalieNOlschewskiHOudizRJAmbrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2Circulation2008117233010301918506008
   PubMed Web of Science ®Google Scholar
• RubinLJBadeschDBBarstRJBosentan therapy for pulmonary arterial hypertensionN Engl J Med20023461289690311907289
   PubMed Web of Science ®Google Scholar
• PeacockAJDawesKEShockAGrayAJReevesJTLaurentGJEndothelin-1 and endothelin-3 induce chemotaxis and replication of pulmonary artery fibroblastsAm J Respir Cell Mol Biol1992754924991419025
   PubMed Web of Science ®Google Scholar
• WedgwoodSDettmanRWBlackSMET-1 stimulates pulmonary arterial smooth muscle cell proliferation via induction of reactive oxygen speciesAm J Physiol Lung Cell Mol Physiol20012815L1058L106711597896
   PubMed Web of Science ®Google Scholar
• BoulangerCLuscherTFRelease of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxideJ Clin Invest19908525875902153712
   PubMed Web of Science ®Google Scholar
• RussellFDSkepperJNDavenportAPEvidence using immunoelectron microscopy for regulated and constitutive pathways in the transport and release of endothelinJ Cardiovasc Pharmacol19983134244309514188
   PubMed Web of Science ®Google Scholar
• ChannickRNSitbonOBarstRJManesARubinLJEndothelin receptor antagonists in pulmonary arterial hypertensionJ Am Coll Cardiol20044312 Suppl S62S67S15194180
   PubMed Web of Science ®Google Scholar
• TakahashiMMatsushitaYIijimaYTanzawaKPurification and characterization of endothelin-converting enzyme from rat lungJ Biol Chem19932682821394213988407980
   PubMed Web of Science ®Google Scholar
• SitbonOMorrellNPathways in pulmonary arterial hypertension: the future is hereEur Respir Rev20122112632132723204120
   PubMedGoogle Scholar
• PollockDMKeithTLHighsmithRFEndothelin receptors and calcium signalingFASEB J1995912119612047672512
   PubMed Web of Science ®Google Scholar
• HirataYEmoriTEguchiSEndothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cellsJ Clin Invest1993914136713737682570
   PubMed Web of Science ®Google Scholar
• ShichiriMKatoHMarumoFHirataYEndothelin-1 as an autocrine/paracrine apoptosis survival factor for endothelial cellsHypertension1997305119812039369276
   PubMed Web of Science ®Google Scholar
• SauvageauSThorinECaronADupuisJEndothelin-1-induced pulmonary vasoreactivity is regulated by ET(A) and ET(B) receptor interactionsJ Vasc Res200744537538117495482
   PubMed Web of Science ®Google Scholar
• TrowTKTaichmanDBEndothelin receptor blockade in the management of pulmonary arterial hypertension: selective and dual antagonismRespir Med2009103795196219304472
   PubMed Web of Science ®Google Scholar
• GatfieldJMueller GrandjeanCSasseTClozelMNaylerOSlow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cellsPLoS One2012710e4766223077657
   PubMed Web of Science ®Google Scholar
• BrudererSHopfgartnerGSeiberlingMAbsorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humansXenobiotica201242990191022458347
   PubMed Web of Science ®Google Scholar
• IglarzMBinkertCMorrisonKPharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonistJ Pharmacol Exp Ther2008327373674518780830
   PubMed Web of Science ®Google Scholar
• AtsmonJDingemanseJShaikevichDVolokhovISidhartaPNInvestigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjectsClin Pharmacokinet201352868569223568224
   PubMed Web of Science ®Google Scholar
• SidhartaPNvan GiersbergenPLDingemanseJSafety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjectsJ Clin Pharmacol201353111131113823900878
   PubMed Web of Science ®Google Scholar
• SidhartaPNDietrichHDingemanseJInvestigation of the effect of macitentan on the pharmacokinetics and pharmacodynamics of warfarin in healthy male subjectsClin Drug Investig2014348545552
   PubMed Web of Science ®Google Scholar
• SpenceSAndersonCCukierskiMPatrickDTeratogenic effects of the endothelin receptor antagonist L-753,037 in the ratReprod Toxicol1999131152910080296
   PubMed Web of Science ®Google Scholar
• KuriharaYKuriharaHSuzukiHElevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1Nature199436864737037108152482
   PubMed Web of Science ®Google Scholar
• TaniguchiTAzumaHOkadaYNaikiHHollenbergMDMuramatsuIEndothelin-1-endothelin receptor type A mediates closure of rat ductus arteriosus at birthJ Physiol2001537Pt 257958511731587
   PubMed Web of Science ®Google Scholar
• AversaMPorterSGrantonJComparative safety and tolerability of endothelin receptor antagonists in pulmonary arterial hypertensionDrug Saf201538541943525792028
   PubMed Web of Science ®Google Scholar
• GeYBagnallAStricklettPKWebbDKotelevtsevYKohanDECombined knockout of collecting duct endothelin A and B receptors causes hypertension and sodium retentionAm J Physiol Renal Physiol20082956F1635F164018784261
   PubMed Web of Science ®Google Scholar
• NagendranJSutendraGPatersonIEndothelin axis is upregulated in human and rat right ventricular hypertrophyCirc Res2013112234735423233754
   PubMed Web of Science ®Google Scholar
• ShapiroSPollockDMGilliesHFrequency of edema in patients with pulmonary arterial hypertension receiving ambrisentanAm J Cardiol201211091373137722858181
   PubMed Web of Science ®Google Scholar
• CondliffeRElliotCAHurdmanJAmbrisentan therapy in pulmonary hypertension: clinical use and tolerability in a referral centreTher Adv Respir Dis201483717724787237
   PubMed Web of Science ®Google Scholar
• PulidoTAdzerikhoIChannickRNMacitentan and morbidity and mortality in pulmonary arterial hypertensionN Engl J Med2013369980981823984728
   PubMed Web of Science ®Google Scholar
• GalieNHoeperMMGibbsJSSimonneauGLiver toxicity of sitaxentan in pulmonary arterial hypertensionEur Respir J201137247547621282816
   PubMed Web of Science ®Google Scholar
• LingLKucREMaguireJJComparison of endothelin receptors in normal versus cirrhotic human liver and in the liver from endothelial cell-specific ETB knockout miceLife Sci20129113–1471672222365955
   PubMed Web of Science ®Google Scholar
• LepistEIGilliesHSmithWEvaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytesPLoS One201491e8754824498134
   PubMed Web of Science ®Google Scholar
• BarstRJLanglebenDFrostASitaxsentan therapy for pulmonary arterial hypertensionAm J Respir Crit Care Med2004169444144714630619
   PubMed Web of Science ®Google Scholar
• GabbayEFraserJMcNeilKReview of bosentan in the management of pulmonary arterial hypertensionVasc Health Risk Manag20073688790018200808
   PubMedGoogle Scholar
• GalieNBadeschDOudizRAmbrisentan therapy for pulmonary arterial hypertensionJ Am Coll Cardiol200546352953516053970
   PubMed Web of Science ®Google Scholar
• ChannickRNDelcroixMGhofraniHAEffect of macitentan on hospitalizations: results from the SERAPHIN trialJACC Heart Fail2015311825457902
   PubMed Web of Science ®Google Scholar